TLV Partners — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies.
AI & Machine LearningBiotechDeep TechClaymont, US
Dov Gertz(Executive Officer, Director)inOded Kalev(Executive Officer, Director)inIddo Weiner(Executive Officer)in
BoardAndrew Hedin(Director)in
Board seatShahar Tzafrir· per SEC Form D
Co-investorsBessemer Venture PartnersSARAS CAPITALVintage Investment Partners
Arato provides a platform for testing and validating AI agents by simulating realistic multi-turn user conversations to surface issues such as hallucinations, accuracy problems, UX drift, tone, and compliance risks.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareTel Aviv, IL
Tal Salmona(Founder)
Co-investorsJibe VenturesPIPELINE CAPITAL PARTNERS
Converge is an AI-native growth platform for direct-to-consumer brands that automates media buying, attribution analysis, and reporting through agentic AI.
AdTechAI & Machine LearningDirect to ConsumerE-commerceEnterprise SoftwareSaaSNew York City, US
Jan-Henrik Lambrechts(Founder)inJerome Billiet(Founder)inThomas Holvoet(Founder)in
Co-investorsEntourage VenturesY CombinatorBessemer Venture PartnersSARAS CAPITALVintage Investment Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.